Deals In Depth: September 2010
With the largest up-front ever for a Phase II candidate, Abbott's license to Reata's CKD compound bardoloxone topped the September alliance list. J&J expanded into vaccines through the Crucell buy, and Genzyme divested its esoteric testing division Genzyme Genetics to LabCorp for $925 million. Biopharma FOPOs and early-stage VC rounds were the most lucrative financing vehicles in September, with each type bringing in around $180 million of the $691 million total. The majority of device fundraising came from MicroPort Scientific's IPO.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.